Unlock stock picks and a broker-level newsfeed that powers Wall Street.

Check-Cap Leads 3 US Penny Stocks To Monitor

In This Article:

As the U.S. market experiences a downturn with the S&P 500 and Nasdaq Composite facing sharp declines, investors are increasingly cautious about economic prospects and policy impacts. In this context, penny stocks—often representing smaller or newer companies—remain an intriguing area for those seeking potential growth opportunities despite their vintage-sounding name. These stocks can offer affordability and significant upside when backed by solid financials, making them worth monitoring for hidden value in today's market landscape.

Top 10 Penny Stocks In The United States

Name

Share Price

Market Cap

Financial Health Rating

QuantaSing Group (NasdaqGM:QSG)

$3.08

$127.54M

★★★★★★

BAB (OTCPK:BABB)

$0.86379

$6.28M

★★★★★☆

Safe Bulkers (NYSE:SB)

$3.76

$392.77M

★★★★☆☆

Golden Growers Cooperative (OTCPK:GGRO.U)

$4.50

$67.38M

★★★★★★

North European Oil Royalty Trust (NYSE:NRT)

$4.47

$42.83M

★★★★★★

Imperial Petroleum (NasdaqCM:IMPP)

$2.60

$82.81M

★★★★★★

Permianville Royalty Trust (NYSE:PVL)

$1.42

$47.52M

★★★★★★

PHX Minerals (NYSE:PHX)

$4.00

$155.17M

★★★★★☆

Smith Micro Software (NasdaqCM:SMSI)

$1.36

$24.65M

★★★★★☆

CBAK Energy Technology (NasdaqCM:CBAT)

$0.8491

$77.35M

★★★★★☆

Click here to see the full list of 728 stocks from our US Penny Stocks screener.

Let's review some notable picks from our screened stocks.

Check-Cap

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Check-Cap Ltd. is a clinical stage medical diagnostics company developing a capsule-based screening technology using ultra-low-dose X-rays to detect precancerous polyps and other structural abnormalities in the colon, with a market cap of $4.53 million.

Operations: Check-Cap Ltd. currently does not report any revenue segments as it is in the clinical stage of developing its innovative capsule-based screening technology for colon diagnostics.

Market Cap: $4.53M

Check-Cap Ltd., a pre-revenue company with a market cap of US$4.53 million, is developing innovative capsule-based screening technology for colon diagnostics. Despite its unprofitability and negative return on equity, the company has maintained financial stability with no debt and sufficient cash runway exceeding one year based on current free cash flow. Recent management changes have seen David Lontini take an active role as Chairman amidst a volatile share price environment. While Check-Cap's board is relatively inexperienced, shareholders have not faced significant dilution recently, and short-term assets comfortably cover liabilities.